

Registered number: SC178704

**ALCHEMY LABORATORIES LTD**

**ANNUAL REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 DECEMBER 2013**

THURSDAY



\*A3FOK9VC\*

A10

04/09/2014

#176

COMPANIES HOUSE

**ALCHEMY LABORATORIES LTD**

**CONTENTS**

	Page
<b>Company information</b>	1
<b>Strategic Report</b>	2
<b>Directors' Report</b>	3 - 4
<b>Independent Auditors' Report to the members of Alchemy Laboratories Ltd</b>	5 - 6
<b>Profit and Loss Account</b>	7
<b>Balance Sheet</b>	8
<b>Notes to the financial statements</b>	9 - 18

**ALCHEMY LABORATORIES LTD**

**COMPANY INFORMATION**

**DIRECTORS**

L D Rees  
R Lamotte  
L Taylor  
J McNamara (appointed 16 January 2013)

**REGISTERED NUMBER**

SC178704

**REGISTERED OFFICE**

8 Tom McDonald Avenue  
Medipark  
Dundee  
DD2 1NH

**INDEPENDENT AUDITORS**

PricewaterhouseCoopers LLP  
Chartered Accountants and Statutory Auditors  
One Kingsway  
Cardiff  
CF10 3PW

## **ALCHEMY LABORATORIES LTD**

### **STRATEGIC REPORT FOR THE YEAR ENDED 31 DECEMBER 2013**

The directors present their Strategic Report of Alchemy Laboratories Ltd (the "company") for the year ended 31 December 2013.

#### **BUSINESS REVIEW**

During the year, as part of an internal group reorganisation within the BBI Holdings group, ownership of the company transferred to BBI Solutions OEM Limited, a wholly owned subsidiary of BBI Holdings Limited.

On 1 November 2013, the trade, assets and liabilities of the company were hived up into BBI Solutions OEM Limited, for consideration equal to the net book value of the net assets transferred resulting in no profit or loss on the transfer.

Following the transfer of trade and net assets, a dividend was declared to clear the reserves of the company. The company has remained dormant since then and management currently have no intentions to recommence any activity.

#### **PRINCIPAL RISKS AND UNCERTAINTIES**


Given that the company is now dormant the directors do not consider there to be any principal risks or uncertainties facing the company.

#### **FINANCIAL KEY PERFORMANCE INDICATORS**

Following the company becoming dormant in the year, the directors do not consider it to be appropriate or relevant to provide an analysis of Key Performance Indicators. The performance of the business, therefore, will be considered as part of the review in the transferee company.

This report was approved by the board on 1 September 2014 and signed on its behalf by:

**L D Rees**  
Director



## **ALCHEMY LABORATORIES LTD**

### **DIRECTORS' REPORT FOR THE YEAR ENDED 31 DECEMBER 2013**

The directors present their annual report and the audited financial statements of Alchemy Laboratories Ltd (the "company") for the year ended 31 December 2013.

#### **PRINCIPAL ACTIVITIES**

The company's principal activities were:

- The manufacture and supply of gold colloid, conjugates and reagents for use in diagnostic tests.
- The provision of contract research and development.
- Contract manufacture and supply of diagnostic point of care tests.

The company's customer base was diverse covering the world's leading Diagnostic businesses and some less established businesses that leveraged the company's expertise in diagnostic test development and manufacture. The company also supplied a wide range of research customers.

On 1 November 2013, the trade, assets and liabilities of the company were hived up into BBI Solutions OEM Limited, for consideration equal to the net book value of the net assets transferred resulting in no profit or loss on the transfer.

Following the transfer of trade and net assets, a dividend was declared to clear the reserves of the company. The company has remained dormant since then and management currently have no intentions to recommence any activity.

#### **DIVIDENDS**

During the year dividends of £5,222k and £1,336k, equivalent to £52k and £1,336k (2012: £Nil) per £1 ordinary share respectively, were paid which reduced the reserves of the company to £Nil.

#### **FUTURE DEVELOPMENTS**

As the company has transferred its trade, assets and liabilities to BBI Solutions OEM Limited a review of future developments is not considered to be necessary.

#### **RESEARCH AND DEVELOPMENT**

Up until the transfer of the trade, assets and liabilities of the company to BBI Solutions OEM Limited the company continued to invest in research and development of platforms, applications and products that would maintain its competitive advantage within the diagnostic market. Investment in research and development was integral to the ongoing success of the business and ensured that our contract research and development customers retained the best service and access to the next generation of quality products. Research and development costs of £709k were incurred during the year (2012: £727k).

#### **FINANCIAL RISK MANAGEMENT**

As the company is now dormant the directors do not consider there to be any financial risks facing the company.

#### **DIRECTORS**

The directors of the company who served during the year and up to the date of signing the financial statements were:

L D Rees  
R Lamotte  
L Taylor  
J McNamara (appointed 16 January 2013)

## **ALCHEMY LABORATORIES LTD**

### **DIRECTORS' REPORT FOR THE YEAR ENDED 31 DECEMBER 2013**

#### **DIRECTORS' RESPONSIBILITIES STATEMENT**

The directors are responsible for preparing the Strategic Report, Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have prepared the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

#### **DISCLOSURE OF INFORMATION TO AUDITORS**


Each of the persons who are directors at the time when this Directors' Report is approved has confirmed that:

- so far as that director is aware, there is no relevant audit information of which the company's auditors are unaware; and
- that director has taken all the steps that ought to have been taken as a director in order to be aware of any information needed by the company's auditors in connection with preparing their report and to establish that the company's auditors are aware of that information.

#### **INDEPENDENT AUDITORS**

The auditors, PricewaterhouseCoopers LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

This report was approved by the board on 1 September 2014 and signed on its behalf by:



**L D Rees**  
Director

## **ALCHEMY LABORATORIES LTD**

### **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF ALCHEMY LABORATORIES LTD**

#### **Report on the company financial statements**

##### **Our opinion**

In our opinion the financial statements, defined below:

- give a true and fair view of the state of the company's affairs as at 31 December 2013 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

This opinion is to be read in the context of what we say in the remainder of this report.

##### **What we have audited**

The financial statements, which are prepared by Alchemy Laboratories Ltd, comprise:

- the Profit and Loss Account for the year ended 31 December 2013;
- the Balance Sheet as at 31 December 2013; and
- the Notes to the Financial Statements, which include a summary of significant accounting policies and other explanatory information.

The financial reporting framework that has been applied in their preparation comprises applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In applying the financial reporting framework, the directors have made a number of subjective judgements, for example in respect of significant accounting estimates. In making such estimates, they have made assumptions and considered future events.

##### **What an audit of financial statements involves**

We conducted our audit in accordance with International Standards on Auditing (UK & Ireland) ("ISAs (UK & Ireland)"). An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of:

- whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed;
- the reasonableness of significant accounting estimates made by the directors; and
- the overall presentation of the financial statements.

In addition, we read all the financial and non-financial information in the Annual Report and Financial Statements (the "Annual Report") to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

##### **Opinions on matters prescribed by the Companies Act 2006**

In our opinion the information given in the Strategic Report and Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

**ALCHEMY LABORATORIES LTD**

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF ALCHEMY LABORATORIES LTD**

**Other matters on which we are required to report by exception**

**Adequacy of accounting records and information and explanations received**

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- we have not received all the information and explanations we require for our audit; or
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.

**Directors' remuneration**

Under the Companies Act 2006 we are required to report if, in our opinion, certain disclosures of directors' remuneration specified by law have not been made. We have no exceptions to report arising from this responsibility.


**Responsibilities for the financial statements and the audit**

**Our responsibilities and those of the directors**

As explained more fully in the Directors' Responsibilities Statement set out on page 4, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and ISAs (UK & Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

This report, including the opinions, has been prepared for and only for the company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.



Neil Rummings (Senior statutory auditor)  
for and on behalf of PricewaterhouseCoopers LLP  
Chartered Accountants and Statutory Auditors  
Cardiff

1 September 2014



**ALCHEMY LABORATORIES LTD**

**PROFIT AND LOSS ACCOUNT  
FOR THE YEAR ENDED 31 DECEMBER 2013**

	<b>Note</b>	<b>2013 £000</b>	<b>2012 £000</b>
<b>TURNOVER</b>	1,2	<b>3,375</b>	<b>4,781</b>
Cost of sales		<u>(2,157)</u>	<u>(2,923)</u>
<b>GROSS PROFIT</b>		<b>1,218</b>	<b>1,858</b>
Administrative expenses		<u>(574)</u>	<u>(866)</u>
<b>OPERATING PROFIT</b>	3	<b>644</b>	<b>992</b>
<b>PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION</b>		<b>644</b>	<b>992</b>
Tax on profit on ordinary activities	7	<u>-</u>	<u>(227)</u>
<b>PROFIT FOR THE FINANCIAL YEAR</b>	15	<b>644</b>	<b>765</b>

All amounts relate to discontinuing operations.

There is no material differences between the profit on ordinary activities before taxation and the profit for the years stated above and their historical cost equivalents.

There were no recognised gains and losses for 2013 or 2012 other than those included in the Profit and Loss Account above and therefore no separate Statement of Total Recognised Gains and Losses has been presented.

The notes on pages 9 to 18 form part of these financial statements.

**ALCHEMY LABORATORIES LTD**  
**REGISTERED NUMBER: SC178704**

**BALANCE SHEET**  
**AS AT 31 DECEMBER 2013**

	Note	£000	2013 £000	£000	2012 £000
<b>FIXED ASSETS</b>					
Tangible assets	8		-		625
<b>CURRENT ASSETS</b>					
Stocks	9	-		392	
Debtors: amounts falling due after more than one year	10	-		4,370	
Debtors: amounts falling due within one year	10	-		1,128	
Cash at bank and in hand		-		483	
				<u>6,373</u>	
<b>CREDITORS: amounts falling due within one year</b>	11	-		<u>(439)</u>	
<b>NET CURRENT ASSETS</b>					<u>5,934</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>					<u>6,559</u>
<b>CREDITORS: amounts falling due after more than one year</b>	12				(644)
<b>PROVISIONS FOR LIABILITIES</b>					
Deferred tax	13				(1)
<b>NET ASSETS</b>					<u><u>5,914</u></u>
<b>CAPITAL AND RESERVES</b>					
Called up share capital	14				-
Share premium account	15				2
Profit and loss account	15				5,912
<b>TOTAL SHAREHOLDERS' FUNDS</b>	16				<u><u>5,914</u></u>

The financial statements on pages 7 to 18 were approved and authorised for issue by the board and were signed on its behalf on 1 September 2014 by:

**L D Rees**  
 Director



The notes on pages 9 to 18 form part of these financial statements.

## ALCHEMY LABORATORIES LTD

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2013

#### 1. ACCOUNTING POLICIES

##### 1.1 Basis of preparation of financial statements

These financial statements are prepared on a going concern basis, under the historical cost convention and in accordance with the Companies Act 2006 and applicable accounting standards in the United Kingdom. The principal accounting policies, which have been applied consistently throughout the year, are set out below.

##### 1.2 Cash flow

The company is a wholly owned subsidiary of BBI Holdings Limited and is included in the consolidated financial statements of BBI Holdings Limited which are publicly available. Consequently, the company has taken advantage of the exemption from preparing a cash flow statement under the terms of FRS 1 (cash flow statements revised 1996).

##### 1.3 Related party transactions

The company is a wholly owned subsidiary of Alere Inc and has taken advantage of the exemption conferred by Financial Reporting Standard 8 'Related party disclosures' not to disclose transactions with Alere Inc or other wholly owned subsidiaries within the group.

##### 1.4 Turnover

Turnover represents amounts receivable for goods and services provided in the normal course of business, net of trade discounts, VAT and other sales related taxes.

Revenue is recognised on despatch of the related goods. Revenue in respect of research and development contracts is recognised as it is earned under the terms of the contract.

##### 1.5 Grants

Grants of a revenue nature are credited to the Profit and Loss Account in line with the related expenditure.

##### 1.6 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less accumulated depreciation. Cost includes the original purchase price of the asset and the costs attributable of bringing the asset to its working condition for its intended use.

Depreciation is provided to write off the cost, less estimated residual values, of all tangible fixed assets evenly over their expected useful lives. It is calculated at the following rates;

Long term leasehold property	-	10% straight line
Plant and machinery	-	10 - 33% straight line
Fixtures and fittings	-	20% straight line

##### 1.7 Leased assets

Operating leases and their annual rentals are charged to the Profit and Loss Account on a straight-line basis over the term of the lease.

## ALCHEMY LABORATORIES LTD

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2013

#### 1. ACCOUNTING POLICIES (continued)

##### 1.8 Stocks

Stocks are valued at the lower of cost and net realisable value. Cost is determined on a first in, first out basis and includes transport and handling costs. In the case of manufactured products cost includes all direct expenditure and production overheads based on normal levels of activities. Net realisable value is based on estimated selling price in the ordinary course of business, less applicable variable selling expenses. Where necessary a provision is made for obsolete or slow moving stock.

##### 1.9 Current and deferred taxation

The current tax expense comprises current and deferred tax. The current tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date.

Where relief is claimed against losses sustained by other group companies in the group, this relief is charged to the company by the donor company at the rate of £1 for every £1 of taxation not paid. Amounts payable for group relief are included in the taxation charge of the company.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date, where transactions or events that result in an obligation to pay more tax in the future or a right to pay less tax in the future have occurred at the balance sheet date.

A net deferred tax asset is recognised as recoverable and therefore recognised only when, on the basis of all available evidence, it can be regarded as more likely than not that there will be suitable taxable profits against which to recover carried forward tax losses and from which the future reversal of underlying timing differences can be deducted.

Deferred tax is measured at the average tax rates that are expected to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date. Deferred tax is measured on a non-discounted basis.

##### 1.10 Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the balance sheet date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Profit and Loss Account.

##### 1.11 Research and development

Research and development expenditure is written off in the Profit and Loss account in the period in which it is incurred.

##### 1.12 Pensions

The company contributes to a defined contribution pension scheme for certain employees. The assets of the defined contribution scheme are held separately from those of the company in independently administered funds.

Contributions to the company's defined contribution pension scheme are charged to the Profit and Loss Account in the year in which they become payable.

## ALCHEMY LABORATORIES LTD

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2013

#### 2. TURNOVER

The whole of the turnover is attributable to the principal activity of the company.

A geographical analysis of turnover is as follows:

	2013 £000	2012 £000
United Kingdom	688	1,195
Rest of European Union	904	1,179
Rest of World	372	429
North America	1,411	1,978
	<u>3,375</u>	<u>4,781</u>

#### 3. OPERATING PROFIT

The operating profit is stated after charging/(crediting):

	2013 £000	2012 £000
Depreciation of tangible fixed assets:		
- owned by the company	88	130
Operating lease rentals:		
- other operating leases	133	133
Foreign exchange	(7)	52
Research and development expenditure	709	727
Other non-operating income	(15)	-
	<u>          </u>	<u>          </u>

#### 4. AUDITORS' REMUNERATION

	2013 £000	2012 £000
Fees payable to the company's auditors for the audit of the company's annual financial statements	<u>3</u>	<u>14</u>

**ALCHEMY LABORATORIES LTD**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2013**

**5. STAFF COSTS**

Staff costs, including directors' remuneration, were as follows:

	<b>2013</b>	2012
	<b>£000</b>	£000
Wages and salaries	<b>1,335</b>	1,535
Social security costs	<b>124</b>	137
Other pension costs	<b>45</b>	51
	<u><b>1,504</b></u>	<u>1,723</u>

The average monthly number of employees, including the directors, during the year was as follows:

	<b>2013</b>	2012
	<b>Number</b>	Number
Directors	<b>1</b>	1
Sales and distribution	<b>2</b>	1
Development and manufacture	<b>65</b>	61
Administration	<b>3</b>	2
	<u><b>71</b></u>	<u>65</u>

On 1 April 2013, all staff contracts were transferred to a fellow subsidiary, BBI Resources Limited, and costs associated with relevant staff have been recharged to the company since that date.

The information disclosed above represents the full cost and the average number of employees up to the date of cessation of trade that were directly engaged on the company's business regardless of where the contract of employment was located.

**6. DIRECTORS' REMUNERATION**

	<b>2013</b>	2012
	<b>£000</b>	£000
Aggregate emoluments	<u><b>-</b></u>	<u>34</u>
Company pension contributions to defined contribution pension schemes	<u><b>-</b></u>	<u>3</u>

During the year retirement benefits were accruing to no directors (2012: 1) in respect of defined contribution pension schemes.

On 1 April 2013, the contracts of L Rees and L Taylor were transferred to a fellow subsidiary, BBI Resources Limited, and the associated costs have been recharged to BBI Holdings Limited where they are remunerated for their services to the group as a whole. J McNamara is not remunerated for his service to the BBI group. It is not practicable to allocate their remuneration for their services as a director between group companies.

**ALCHEMY LABORATORIES LTD**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2013**

**7. TAX ON PROFIT ON ORDINARY ACTIVITIES**

	<b>2013</b>	<b>2012</b>
	<b>£000</b>	<b>£000</b>
<b>Analysis of tax charge in the year</b>		
<b>Current tax</b>		
UK corporation tax charge on profit for the year	-	207
<b>Deferred tax</b>		
Origination and reversal of timing differences	-	(10)
Adjustment in respect of prior periods	-	30
<b>Total deferred tax</b> (see note 13)	<u>-</u>	<u>20</u>
<b>Tax on profit on ordinary activities</b>	<u>-</u>	<u>227</u>

**Factors affecting tax charge for the year**

The tax assessed for the year is lower than (2012: lower than) the standard rate of corporation tax in the UK of 23.25% (2012: 24.5%). The differences are explained below:

	<b>2013</b>	<b>2012</b>
	<b>£000</b>	<b>£000</b>
Profit on ordinary activities before tax	<u>644</u>	<u>992</u>
Profit on ordinary activities multiplied by standard rate of corporation tax in the UK of 23.25% (2012: 24.5%)	<b>150</b>	<b>243</b>
<b>Effects of:</b>		
Expenses not deductible for tax purposes	<b>114</b>	<b>7</b>
Capital allowances less than depreciation	<b>(4)</b>	<b>10</b>
Adjustments in respect of prior years	<b>29</b>	<b>-</b>
Income not taxable for tax purposes	<b>(140)</b>	<b>-</b>
Adjustment for research and development tax credit	<b>-</b>	<b>(53)</b>
Assumed by transferee company on transfer of trade and assets	<b>(149)</b>	<b>-</b>
<b>Current tax charge for the year</b>	<u>-</u>	<u>207</u>

**Factors that may affect future tax charges**

The March 2013 Budget Statement announced changes to the UK Corporation tax rates that were substantively enacted as part of the Finance Bill 2013 on 2 July 2013. These reduced the main rate of corporation tax to 21% from 1 April 2014 and to 20% from 1 April 2015. As the changes have been substantively enacted at the balance sheet date their effects are included in these financial statements. Accordingly, the deferred tax balance has been calculated using a rate of 20%. No further changes to future tax rates were announced in the March 2014 Budget Statement on 19 March 2014.

As per the Strategic Report, the trade and assets of Alchemy Laboratories Limited were transferred to BBI Solutions OEM Limited during the accounting period. As part of this the tax charge and liability for the year ending 31 December 2013 has been borne by BBI Solutions OEM Limited.

**ALCHEMY LABORATORIES LTD**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2013**

**8. TANGIBLE FIXED ASSETS**

	Long Term Leasehold Property £000	Plant and machinery £000	Fixtures and fittings £000	Total £000
<b>Cost</b>				
At 1 January 2013	272	903	53	1,228
Additions	8	54	-	62
Transferred to group company	(280)	(778)	(19)	(1,077)
Disposals	-	(179)	(34)	(213)
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 December 2013	-	-	-	-
	<hr/>	<hr/>	<hr/>	<hr/>
<b>Accumulated depreciation</b>				
At 1 January 2013	54	503	46	603
Charge for the year	24	62	2	88
Transferred to group company	(78)	(386)	(14)	(478)
On disposals	-	(179)	(34)	(213)
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 December 2013	-	-	-	-
	<hr/>	<hr/>	<hr/>	<hr/>
<b>Net book value</b>				
At 31 December 2013	-	-	-	-
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 December 2012	218	400	7	625
	<hr/>	<hr/>	<hr/>	<hr/>

**9. STOCKS**

	2013 £000	2012 £000
Raw materials	-	346
Finished goods and goods for resale	-	46
	<hr/>	<hr/>
	-	392
	<hr/>	<hr/>

The difference between purchase price or production cost of stocks and their replacement cost is not material.



ALCHEMY LABORATORIES LTD

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2013

10. DEBTORS

	2013 £000	2012 £000
<b>Due after more than one year</b>		
Amounts owed by fellow subsidiaries	-	4,370
	<u>          </u>	<u>          </u>

	2013 £000	2012 £000
<b>Due within one year</b>		
Trade debtors	-	727
Amounts owed by group companies	-	324
Other debtors	-	53
Prepayments and accrued income	-	24
	<u>          </u>	<u>          </u>
	<u>          </u>	<u>          </u>
	-	1,128

11. CREDITORS:  
Amounts falling due within one year

	2013 £000	2012 £000
Trade creditors	-	34
Other taxation and social security	-	90
Accruals and deferred income	-	315
	<u>          </u>	<u>          </u>
	<u>          </u>	<u>          </u>
	-	439

12. CREDITORS:  
Amounts falling due after more than one year

	2013 £000	2012 £000
Amounts owed to fellow subsidiaries	-	644
	<u>          </u>	<u>          </u>

ALCHEMY LABORATORIES LTD

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2013

13. DEFERRED TAXATION

	2013 £000	2012 £000
At beginning of year	1	(19)
(Charged)/credited to the Profit and Loss Account	-	(10)
Adjustment in respect of previous years	-	30
Transferred to group company	(1)	-
	<u>          </u>	<u>          </u>
At end of year	<u>          </u> -	<u>          </u> 1

The provision for deferred taxation is made up as follows:

	2013 £000	2012 £000
Accelerated capital allowances	<u>          </u> -	<u>          </u> 1

14. CALLED UP SHARE CAPITAL

	2013 £	2012 £
<b>Allotted, called up and fully paid</b>		
1 (2012: 100) Ordinary share of £1 (2012: £1)	<u>          </u> 1	<u>          </u> 100

On 20 December 2013, the company reduced its share capital from 100 ordinary shares of £1 each to one share of £1 each using the directors' solvency statement procedure under the Companies Act 2006. All amounts arising from the reduction were credited to distributable reserves.

15. PROFIT AND LOSS ACCOUNT

	Share premium account £000	Profit and Loss Account £000
At 1 January 2013	2	5,912
Profit for the financial year	-	644
Dividends (note 17)	-	(6,558)
Cancellation of Share premium account	(2)	2
	<u>          </u>	<u>          </u>
At 31 December 2013	<u>          </u> -	<u>          </u> -

16. RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS

	2013 £000	2012 £000
Opening shareholders' funds	5,914	5,149
Profit for the financial year	644	765
Dividends (Note 17)	(6,558)	-
	<u>          </u>	<u>          </u>
Closing shareholders' funds	<u>          </u> -	<u>          </u> 5,914

**ALCHEMY LABORATORIES LTD**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2013**

**17. DIVIDENDS**

	2013 £000	2012 £000
<b>Ordinary</b>		
Interim dividend of £52k (2012: £Nil) per £1 ordinary share	5,222	-
Interim dividend of £1,336k (2012: £Nil) per £1 ordinary share	1,336	-
	<u>6,558</u>	<u>-</u>

**18. CONTINGENT LIABILITIES**

In the prior year, the company guaranteed the loan facilities of other group companies. At 31 December 2012, the potential liability was £Nil (2012: £1.304k).

The company has a guarantee of £20,000 (2012: £20,000) in favour of HM Revenue & Customs for duty deferment bonds.

**19. PENSION COMMITMENTS**

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company, in an independently administered fund. The pension charge amounted to £45k (2012: £51k). There were no outstanding or prepaid contributions at either the beginning or end of the financial year.

**20. OPERATING LEASE COMMITMENTS**

At 31 December the company had annual commitments under non-cancellable operating leases as follows:

	<b>Land and buildings</b>	
	2013 £000	2012 £000
<b>Expiry date:</b>		
Within 1 year	-	10
After more than 5 years	-	122
Total	<u>-</u>	<u>132</u>

**21. RELATED PARTY TRANSACTIONS**

The company is a wholly owned subsidiary of Alere Inc and has taken advantage of the exemption conferred by Financial Reporting Standard 8 'Related party disclosures' not to disclose transactions with Alere Inc or other wholly owned subsidiaries within the group.

During the year ended 31 December 2013, the company was invoiced by Hornbuckle Mitchell Trustees for £69,697 (2012: £76k) in relation to annual rent of its facility. The pension fund of Richard Lamotte, a director of Alchemy Laboratories Ltd, is the direct beneficiary of this trust. £Nil remained outstanding at 31 December 2013 (2012: £Nil).

**ALCHEMY LABORATORIES LTD**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2013**

**22. ULTIMATE PARENT UNDERTAKING AND CONTROLLING PARTY**

The company is a wholly owned subsidiary of BBI Solutions OEM Limited, which is incorporated in England and Wales. BBI Solutions OEM Limited is ultimately owned and controlled by Alere Inc, a company incorporated in the United States of America and who the directors regard as the ultimate controlling party.

BBI Holdings Limited is the smallest company in the group which prepares consolidated financial statements. Copies of the consolidated financial statements can be obtained from the Company Secretary at Haywood House, Dumfries Place, Cardiff CF10 3GA.

Alere Inc is the largest company in the group which prepares consolidated financial statements. Copies of the consolidated financial statements can be obtained from: Alere Inc, 51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453-3448.